Chlorpromazine-induced lenticular opacity.
Srinivasan K, Gopalakrishna M.
Indian J Pharmacol. 2020 Jul-Aug;52(4):339-340. doi: 10.4103/ijp.IJP_691_20.
Ocular adverse effects of common psychotropic agents: a review.
Richa S, Yazbek JC.
CNS Drugs. 2010 Jun;24(6):501-26. doi: 10.2165/11533180-000000000-00000.
Cataract occurrence with antipsychotic drugs.
Shahzad S, Suleman MI, Shahab H, Mazour I, Kaur A, Rudzinskiy P, Lippmann S.
Psychosomatics. 2002 Sep-Oct;43(5):354-9. doi: 10.1176/appi.psy.43.5.354.
Chlorpromazine induced cataract in a young patient with schizophrenia.
Divakaran A, Rao NP, Venkatasubramanian G, Behere RV, Varambally S, Gangadhar BN.
Indian J Psychol Med. 2010 Jan;32(1):69-70. doi: 10.4103/0253-7176.70546.
Cataract prevalence and prevention in Europe: a literature review.
Prokofyeva E, Wegener A, Zrenner E.
Acta Ophthalmol. 2013 Aug;91(5):395-405. doi: 10.1111/j.1755-3768.2012.02444.x. Epub 2012 Jun 20.
Clozapine-induced cataract in a young female.
Alam MS, Praveen Kumar KV.
J Pharmacol Pharmacother. 2016 Oct-Dec;7(4):184-186. doi: 10.4103/0976-500X.195904.
Chlorpromazine-induced refractile corneal deposits and cataract.
Leung AT, Cheng AC, Chan WM, Lam DS.
Arch Ophthalmol. 1999 Dec;117(12):1662-3. doi: 10.1001/archopht.117.12.1662.
Experimental chlorpromazine cataracts.
Howard RO, McDonald CJ, Dunn B, Creasey WA.
Invest Ophthalmol. 1969 Aug;8(4):413-21.
[Research relating the use of systematic drug and cataracts].
Lei JY, Yao K.
Zhonghua Yan Ke Za Zhi. 2013 May;49(5):468-71.
The use of chlorpromazine in cataract surgery; a preliminary report.
HARLEY RD, MISHLER JE.
Am J Ophthalmol. 1957 May;43(5):744-54. doi: 10.1016/0002-9394(57)91515-5.
